


Starting right with RYTARY

In this handy pocket guide, you'll find the most important information to keep in mind as you begin your new treatment.



INDICATION

RYTARY is a prescription medication that contains a combination of carbidopa and levodopa for the treatment of Parkinson's disease, Parkinson's disease caused by infection or inflammation of the brain, or Parkinson's disease like symptoms that may result from carbon monoxide or manganese poisoning.

IMPORTANT SAFETY INFORMATION

Do not take RYTARY with antidepressant medications known as nonselective monoamine oxidase (MAO) inhibitors because taking these two drugs within two weeks of each other can result in high blood pressure.

Taking RYTARY may result in falling asleep while engaged in normal activities, even without warning and as late as one year after starting to take RYTARY. Other sedating medicines and alcohol taken together with RYTARY may have additional sedative effects. Tell your healthcare provider if you have any kind of sleep disorder or are experiencing drowsiness or sleepiness.

Please see additional Important Safety Information on adjacent pages and accompanying full Prescribing Information.

RYTARY[®]
(carbidopa and levodopa)
EXTENDED-RELEASE CAPSULES
23.75 mg/95 mg • 36.25 mg/145 mg
48.75 mg/195 mg • 61.25 mg/245 mg



RYTARY works differently than immediate-release (IR) treatment.

While RYTARY is a combination of carbidopa (CD) and levodopa (LD), it is an extended-release form of the medication.

This means that, unlike IR CD/LD (which works quickly but may not work for very long), each dose of RYTARY works quickly, and keeps working for up to 4 to 5 hours. This may reduce the amount of “off” time you experience.

That said, your initial dose of RYTARY may need to be adjusted, which is why it’s important to update your healthcare provider early and often about your progress.

IMPORTANT SAFETY INFORMATION (continued)

Some side effects of taking RYTARY including sleepiness and dizziness may affect your ability to drive or operate machinery. Do not drive a car, operate a machine, or do anything that requires you to be alert until you know how RYTARY affects you.



Your healthcare provider may need to adjust your dose.

Dose adjustments may be required during your treatment with RYTARY. While some people find that their first dose of RYTARY works for them, others will need to have their dose adjusted.

But in order for your healthcare provider to find the dose that's right for you, you need to be open and honest about how you're doing.

Discussing your response to treatment with your healthcare provider may enable the best possible results.

IMPORTANT SAFETY INFORMATION (continued)

Talk to your healthcare provider before you lower the dose or stop taking RYTARY, as this may result in serious side effects. Call your healthcare provider immediately if you develop withdrawal symptoms such as fever, confusion, or severe muscle stiffness.



Finding the right
dose of RYTARY
may take time.

Please see additional Important Safety Information on adjacent pages
and accompanying full Prescribing Information.

The goal is to find the dose of RYTARY that can help you feel like you've *still got it*.

Your first few days and weeks on RYTARY are especially important, because it may take time for your body to adjust to your new medication. Pay close attention to what your body is telling you, and report your progress to your healthcare provider. Pay particularly close attention to whether you're experiencing:

- Too much "off" time
- A delay in "on" time
- Too much dyskinesia

If you are not having the RYTARY experience you hoped for,
let your healthcare provider know right away.

RYTARY[®]
(carbidopa and levodopa)

EXTENDED-RELEASE CAPSULES
23.75 mg/95 mg • 36.25 mg/145 mg
48.75 mg/195 mg • 61.25 mg/245 mg

IMPORTANT SAFETY INFORMATION (continued)

Make sure to tell your healthcare provider if you have any heart conditions, especially if you have had a heart attack and also have irregular heartbeats. Some people with a history of or risk factors for heart disease have experienced heart problems while taking RYTARY.

Some patients taking RYTARY can experience hallucinations (unreal visions, sounds, or sensations) or abnormal thoughts and behaviors (such as excessive suspicion, believing things that are not real, confusion, agitation, aggressive behavior, and disorganized thinking). If you have hallucinations or abnormal thoughts or behaviors, talk with your healthcare provider.

Some patients taking certain medicines to treat Parkinson's disease have intense urges to gamble, increased sexual urges, other intense urges, and the inability to control those urges. If you or your family members notice that you are developing unusual urges or behaviors, talk to your healthcare provider.

Tell your healthcare provider if abnormal involuntary movements appear or get worse during treatment with RYTARY.

Tell your healthcare provider if you have ever had a peptic ulcer, because RYTARY may increase your chances of having bleeding in your stomach.

Tell your healthcare provider if you have glaucoma, because RYTARY may increase the pressure in your eyes.

Parkinson's disease patients are at an increased risk of developing melanoma, a form of skin cancer. See your healthcare provider for regular skin examinations when taking RYTARY.

The most common side effects that may occur with RYTARY include nausea, dizziness, headache, sleeplessness, abnormal dreams, dry mouth, abnormal involuntary movements, anxiety, constipation, vomiting, and low blood pressure upon rising. Rise slowly after sitting or lying down for a prolonged period.

Following use in the marketplace, some patients taking RYTARY have experienced suicidal thoughts or have attempted suicide. A causal relationship has not been established. Tell your healthcare provider if you have thoughts of suicide or have attempted suicide.

Notify your healthcare provider if you become pregnant or intend to become pregnant during therapy or if you intend to breast-feed or are breast-feeding an infant.

Adverse events following unintentional overdose with this medication have been reported. If you accidentally take more than your prescribed dose, talk to your healthcare provider right away.

Please see additional Important Safety Information on adjacent pages and accompanying full Prescribing Information.

IMPORTANT SAFETY INFORMATION (continued)

Make sure you tell your healthcare provider about all of the prescription and non-prescription medications you take, including supplements, and especially those for Parkinson's disease, heart disease, blood pressure, abnormal thoughts, tuberculosis, and sleep problems, and supplements containing iron. Do not take other carbidopa levodopa preparations with RYTARY without consulting your healthcare provider.

Be sure to take your medicine as instructed. You may take RYTARY with or without food; however, taking RYTARY with food may decrease or delay its effect. For this reason, consider taking the first dose of the day about 1 to 2 hours before eating. Swallow RYTARY whole; do not chew, divide, or crush. If you have difficulty swallowing the capsule, twist

apart both halves and sprinkle the entire contents of both halves of the capsule on a small amount of applesauce (1 to 2 tablespoons). Consume the mixture immediately. Do not store the drug/food mixture for future use.

Note: The above information for patients being treated with RYTARY is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects. Tell your healthcare provider if you have any side effects while taking RYTARY. He or she can make adjustments that may reduce these effects.

To report SUSPECTED ADVERSE REACTIONS, contact Amneal Specialty, a division of Amneal Pharmaceuticals LLC at 1-877-835-5472 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see additional Important Safety Information on adjacent pages and accompanying full Prescribing Information.

STILL GOT QUESTIONS? TALK TO YOUR HEALTHCARE PROVIDER OR VISIT RYTARY.COM



RYTARY® is a registered trademark of Impax Laboratories, LLC.

© 2019 Amneal Pharmaceuticals LLC.

Distributed by Amneal Specialty, a division of Amneal Pharmaceuticals LLC.

All rights reserved. Printed in USA. PP-PAT-RYT-US-0160 06/2019

RYTARY®
(carbidopa and levodopa)

EXTENDED-RELEASE CAPSULES

23.75 mg/95 mg • 36.25 mg/145 mg

48.75 mg/195 mg • 61.25 mg/245 mg